Zanubrutinib in MCL

Zanubrutinib in MCL

obr

1 month
5 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, tells us about the patient profile most suited for zanubrutinib in relapsed/refractory mantle cell lymphoma (MCL).
Up Next Autoplay